Ikarian Capital’s Cabaletta Bio CABA Stock Holding History

Ikarian Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Sell	700,000 -200,000	-22%	-$658K	0.23%	86
2026 Q1	$2.42M	Hold	900,000	–	–	0.2%	89
2025 Q4	$1.97M	Buy	+900,000	New	+$2.23M	0.15%	102
2024 Q1	–	Sell	-216,620	Closed	-$4.65M	–	146
2023 Q4	$4.92M	Buy	+216,620	New	+$3.64M	0.46%	59
2023 Q1	–	Sell	-30,286	Closed	-$280K	–	121
2022 Q4	$280K	Sell	30,286 -138,337	-82%	-$504K	0.07%	69
2022 Q3	$109K	Sell	168,623 -775,808	-82%	-$934K	0.02%	98
2022 Q2	$1M	Sell	944,431 -75,639	-7%	-$107K	0.18%	75
2022 Q1	$2.07M	Buy	1,020,070 +49,672	+5%	+$130K	0.27%	68
2021 Q4	$3.68M	Sell	970,398 -217,500	-18%	-$2.32M	0.55%	42
2021 Q3	$14.4M	Buy	1,187,898 +240,770	+25%	+$2.22M	1.02%	23
2021 Q2	$8.14M	Buy	947,128 +557,744	+143%	+$5.48M	0.66%	43
2021 Q1	$4.32M	Buy	+389,384	New	+$4.76M	0.15%	132

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ikarian Capital's CABA Position: Q2 2026 in Review

Ikarian Capital reduced its Cabaletta Bio (CABA) stake by 22% in Q2 2026, selling an estimated $658K and leaving 700,000 shares worth $2.18M. The position accounts for 0.23% of the portfolio, ranked #86.

Ikarian Capital first reported a position in CABA in Q1 2021 and has held it in 12 quarters since. The position peaked at $14.4M in Q3 2021. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Ikarian Capital held 700,000 shares of Cabaletta Bio worth $2.18M as of Q2 2026.
Ikarian Capital sold 200,000 Cabaletta Bio shares in Q2 2026, an estimated $658K.
Cabaletta Bio made up 0.23% of Ikarian Capital's portfolio in Q2 2026, its #86 holding.
Ikarian Capital first reported a position in Cabaletta Bio in Q1 2021 and has held it in 12 quarters since.
Ikarian Capital's Cabaletta Bio position peaked at $14.4M in Q3 2021.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.